Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

J. Janssen, B. Lowenberg, M. Manz, M. Bargetzi, B. Biemond, P.V. Borne, D. Breems, R. Brouwer, Y. Chalandon, D. Deeren, A. Efthymiou, B.T. Gjertsen, C. Graux, M. Gregor, D. Heim, U. Hess, M. Hoogendoorn, A. Jaspers, A.S. Jie, M. Jongen-LavrencicS. Klein, M. van der Klift, J. Kuball, D. van Lammeren-Venema, M.C. Legdeur, A. van de Loosdrecht, J. Maertens, M.V. Kooy, I. Moors, M. Nijziel, F. van Obbergh, M. Oosterveld, T. Pabst, M. van der Poel, H. Sinnige, O. Spertini, W. Terpstra, L. Tick, W. van der Velden, M.C. Vekemans, E. Vellenga, O. de Weerdt, P. Westerweel, G. Stussi, Y. van Norden, G. Ossenkoppele

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number672
Number of pages11
JournalCancers
Volume13
Issue number4
DOIs
Publication statusPublished - 1 Feb 2021

Keywords

  • aminopeptidase inhibitor
  • aml
  • clinical trial
  • elderly
  • high-risk mds
  • tosedostat
  • AML
  • high-risk MDS

Cite this